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To the Editor:
In a recent article by Tsujino 
et al.1 pooled the data from the litera-
ture investigating the effectiveness of 
consolidation chemotherapy (CHT) 
after concurrent radiochemotherapy 
(RT-CHT) in locally advanced non–
small-cell lung cancer (NSCLC). 
They found no difference (survivals, 
toxicity) between RT-CHT followed 
by consolidation CHT and exclusive 
RT-CHT, adding to previous observa-
tions that concurrent RT-CHT is the 
standard treatment in locally advanced 
NSCLC.2–4 Another recent data5 showed 
that concurrent RT-CHT can also be 
considered as one of standards in clini-
cal stage IIIA NSCLC patients.
Although reasons for ineffi-
ciency of consolidation CHT may be 
multiple, it is challenging to disclose 
some aspects that may have adversely 
influenced the outcome. Although these 
studies presented very detailed pat-
tern of failure in general, this was done 
for the whole time period of the study 
(treatment plus follow-up). This way 
we only learned about the total patterns 
of failure and not about which type of 
failure was observed when, that is, after 
concurrent or after consolidation part, 
and particularly in which patients.
Why exact pattern of failure is so 
important? First, there are several types 
of patients after the initial (concurrent) 
part of RT-CHT and they can easily 
be separated regarding the response. 
Although it is extremely unlikely that 
those achieving a stable disease would 
benefit from the consolidation CHT, 
those with either a complete response 
(CR) or a partial response (PR) seem 
as likely candidates (although not all of 
them) to benefit from the consolidation 
CHT. Therefore, separation of pattern of 
failure occurring in likely (CR and PR) 
and unlikely (stable disease) candidates 
could be used for further studies using 
similar design with respect to, for exam-
ple, eligibility criteria. Second, and more 
importantly, among likely candidates 
(CR and PR) to benefit from consolida-
tion CHT, a distinction should be made 
between those achieving CR and those 
achieving PR after concurrent RT-CHT. 
This is so because different mechanisms 
(precisely, different location) of action of 
consolidation CHT would be expected. 
In the CR patients, consolidation CHT 
would target only a microscopic disease 
both intrathoracically and extrathoraci-
cally, whereas in the PR patients, it would 
have also to address clinically overt 
intrathoracic disease. Pattern of failure 
in these two distinct groups of patients 
would then clearly show how and where 
consolidation CHT actually acts and to 
what extent (clinical versus subclinical). 
In addition, we would be able to investi-
gate the determinants of treatment out-
come such as cross-resistance between 
drugs or drugs and RT.
Although identifying pattern of 
failure in patients achieving differ-
ent response after concurrent RT-CHT 
would place additional burden on inves-
tigators and hospitals, this effort would 
be eventually rewarding. This way 
we would be able to identify different 
patient subsets and different options 
and to proceed (or not) with a consoli-
dation CHT, an approach which would 
ultimately lead to a better patient-tai-
lored treatment sequence, a must for a 
future clinical research in lung cancer. 
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